Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 27, 2013

Covance Launches External Laboratory-Management Services

Covance launches external laboratory-management services for clinical trials.

The CRO Covance has launched external laboratory-management services, a new offering that provides biopharmaceutical companies with management solutions for external laboratory testing associated with clinical trials. Covance’s external laboratory management services are designed to increase the quality of clinical- study data by managing specialty laboratory testing for clients along with services provided by a central laboratory.  These services include laboratory selection and qualification, auditing, vendor management, contracting, and data cleaning.  The new services will be managed by a team within Covance's central laboratory services and expands Covance's capabilities in central laboratory testing, biosample management, and data services.

Source: Covance


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.